Your browser is no longer supported. Please, upgrade your browser.
Settings
CVM CEL-SCI Corporation daily Stock Chart
CVM [NYSE]
CEL-SCI Corporation
Index- P/E- EPS (ttm)-1.15 Insider Own4.70% Shs Outstand36.84M Perf Week-12.08%
Market Cap270.77M Forward P/E19.34 EPS next Y0.38 Insider Trans-0.80% Shs Float33.16M Perf Month-14.04%
Income-32.20M PEG- EPS next Q-0.09 Inst Own17.50% Short Float18.56% Perf Quarter15.75%
Sales0.50M P/S541.55 EPS this Y-2.50% Inst Trans0.77% Short Ratio8.90 Perf Half Y9.70%
Book/sh0.03 P/B245.00 EPS next Y226.70% ROA-118.50% Target Price14.00 Perf Year108.81%
Cash/sh0.26 P/C28.50 EPS next 5Y- ROE- 52W Range2.37 - 9.93 Perf YTD156.10%
Dividend- P/FCF- EPS past 5Y24.50% ROI-125.20% 52W High-23.77% Beta3.01
Dividend %- Quick Ratio2.30 Sales past 5Y24.50% Gross Margin- 52W Low219.84% ATR0.62
Employees43 Current Ratio2.50 Sales Q/Q0.00% Oper. Margin- RSI (14)40.88 Volatility6.58% 6.95%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.20% Profit Margin- Rel Volume0.88 Prev Close7.35
ShortableYes LT Debt/Eq12.27 EarningsNov 13 AMC Payout- Avg Volume692.02K Price7.57
Recom- SMA20-11.12% SMA50-7.88% SMA20028.59% Volume403,985 Change2.99%
Mar-02-15Initiated Dawson James Buy $3
Oct-16-19 07:30PM  CVM: IDMC Nod & Target Price Raise Zacks Small Cap Research
Oct-15-19 08:30AM  CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study Business Wire +5.96%
Sep-25-19 11:35AM  CVM: A Focus on LEAPS Zacks Small Cap Research +5.79%
Sep-04-19 12:14PM  CEL-SCI Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference Business Wire
Aug-14-19 04:20PM  CEL-SCI Corporation Reports Third Quarter Fiscal 2019 Financial Results Business Wire
Jul-23-19 09:30AM  CEL-SCIs Scientific Review on Inflammatory Disease Therapies Published in Peer Reviewed Journal International Immunopharmacology Business Wire
Jul-08-19 09:00AM  CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting Business Wire
Jun-23-19 09:00AM  These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now? Motley Fool
Jun-19-19 10:30AM  CVM: No Free Samples on Facility Tour Zacks Small Cap Research
Jun-11-19 04:35PM  The Companies Set To Join The Russell Index July 1 Benzinga -7.17%
Jun-10-19 09:00AM  CEL-SCI Corporation Set to Join Russell 3000® Index Business Wire +21.96%
Jun-03-19 09:00AM  CEL-SCI Corporation to Present at the 9th Annual LD Micro Invitational Business Wire -6.22%
May-29-19 01:00PM  CVM: Second Quarter 2019 Results Zacks Small Cap Research
May-14-19 04:33PM  Cel-Sci: Fiscal 2Q Earnings Snapshot Associated Press
04:20PM  CEL-SCI Corporation Reports Second Quarter Fiscal 2019 Financial Results Business Wire
May-13-19 09:00AM  CEL-SCI Presents New Data for Its LEAPS Vaccine in the Treatment of Rheumatoid Arthritis at the American Association of Immunologists 103rd Annual Meeting Business Wire -5.93%
May-08-19 08:00AM  CEL-SCI Corporation Releases Letter to Shareholders Business Wire +10.91%
Apr-30-19 09:00AM  CEL-SCI to Present at the ThinkEquity Conference Business Wire -6.18%
Mar-29-19 09:00AM  CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study Business Wire +10.62%
Mar-26-19 06:16PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CEL-SCI Corporation GlobeNewswire
Mar-25-19 08:12AM  CEL-SCI Corporation Releases Letter to Shareholders Business Wire
Mar-07-19 11:00AM  CEL-SCI Selected by National Institutes of Health to Showcase Its LEAPS Technology at BIO International Convention Business Wire
Mar-04-19 08:00AM  CEL-SCIs Scientific Article on Vaccines for Autoimmune Disease Published in Journal of Clinical & Cellular Immunology Business Wire
Mar-01-19 11:45AM  CVM: Clinical Trials Update Zacks Small Cap Research
Feb-14-19 04:27PM  Cel-Sci: Fiscal 1Q Earnings Snapshot Associated Press
04:05PM  CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results Business Wire
Feb-07-19 09:00AM  CEL-SCI to Present at 2019 BIO CEO & Investor Conference Business Wire
Feb-04-19 10:00AM  CVM: CEL-SCI: Advancing with an Intent to Cure Zacks Small Cap Research
Feb-01-19 11:30AM  LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index ACCESSWIRE
Jan-23-19 09:20AM  U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology Business Wire
Jan-15-19 08:00AM  CEL-SCI Regains Full Listing Compliance with NYSE American Business Wire +11.28%
Dec-20-18 09:00AM  CEL-SCI Reports Fiscal 2018 Financial Results and Clinical & Corporate Developments Business Wire
Nov-23-18 08:55AM  Investor Expectations to Drive Momentum within Cel-Sci, DGSE Companies, Veracyte, China Pharma, Barnwell Industries, and Silvercrest Asset Management Group Discovering Underlying Factors of Influence GlobeNewswire +6.27%
Oct-23-18 08:30AM  CEL-SCI Receives about $8 Million from Warrant Exercises Business Wire -11.96%
Oct-16-18 10:55AM  CVM: A New Solution in Head & Neck Cancer Zacks Small Cap Research
Oct-01-18 08:30AM  Penny Stocks to Buy Using Technical Analysis for October 2018 Investopedia +5.19%
Sep-28-18 08:00AM  CEL-SCI Announces Warrants to Expire on October 11, 2018 Business Wire
Sep-24-18 10:30AM  Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market ACCESSWIRE
Sep-14-18 09:00AM  CEL-SCI Receives $5.4 Million from Warrant Exercises Business Wire +13.61%
Sep-07-18 09:30AM  Has Cel-Sci (CVM) Outpaced Other Medical Stocks This Year? Zacks +8.08%
Sep-05-18 09:00AM  NIH Selects CEL-SCIs LEAPS Rheumatoid Arthritis Vaccine for Commercialization Accelerator Program Business Wire +5.73%
Aug-22-18 08:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and CEL-SCI ACCESSWIRE -5.56%
Aug-21-18 10:00AM  CEL-SCI Corporation Releases Letter to Shareholders Business Wire +37.29%
Aug-17-18 08:00AM  CEL-SCI Announces That the NYSE American Approves Plan Business Wire +20.40%
Aug-15-18 08:30AM  CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study Business Wire
Aug-14-18 05:13PM  Cel-Sci: Fiscal 3Q Earnings Snapshot Associated Press
04:33PM  CEL-SCI Corporation Reports Third Quarter Fiscal Year 2018 Financial Results Business Wire
Jul-13-18 05:10PM  CEL-SCI Reports on NYSE American Noncompliance Notice and Compliance Plan Business Wire
Jul-10-18 08:10AM  Todays Research Reports on Stocks to Watch: MabVax Therapeutics and CEL-SCI ACCESSWIRE -13.22%
07:30AM  New Catalysts Could Send This $3 Medical Device Stock to $9 ACCESSWIRE
Jul-09-18 09:00AM  CEL-SCI Corporation Issues Letter to Shareholders Business Wire +44.31%
Jul-02-18 12:46PM  CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering Business Wire
Jun-28-18 02:56PM  'The drug was not the problem:' Vienna biotech Cel-Sci wins lawsuit after delayed trial American City Business Journals -33.94%
01:09PM  CEL-SCI Announces $5 Million Registered Direct Offering Business Wire
Jun-27-18 10:51AM  CEL-SCI Receives $2.1 Million from Warrant Exercises Business Wire -40.89%
08:00AM  Cel-Sci Wins Breach of Contract Ruling against Clinical Research Organization inVentiv, Now Known as Syneos Health Business Wire
Jun-11-18 09:00AM  CEL-SCI Corporation Issues Letter to Shareholders Business Wire
Jun-08-18 08:30AM  U.S. Patent Office Allows New CEL-SCI Patents for LEAPS Vaccine Platform Technology Business Wire
Jun-05-18 08:00AM  CEL-SCI to Present Today at the 8th Annual LD Micro Invitational Business Wire
May-30-18 04:15PM  CEL-SCI Announces Reminder of Warrant Exercise Price Business Wire
07:30AM  Wired News Alexion Pharma Announced Acceptance of Offer by Wilson Therapeutics ACCESSWIRE
May-22-18 08:00AM  CEL-SCI Corporation to Present at the 8th Annual LD Micro Invitational Business Wire
May-15-18 04:43PM  Cel-Sci: Fiscal 2Q Earnings Snapshot Associated Press -8.65%
04:20PM  CEL-SCI Corporation Reports Second Quarter Fiscal 2018 Financial Results Business Wire
May-08-18 08:30AM  Today's Research Reports on Trending Tickers: Cel-Sci Corporation and Brainstorm Cell Therapeutics ACCESSWIRE
May-02-18 09:00AM  CEL-SCI Corporation Announces Upcoming Investor Conference Presentations Business Wire +5.38%
Apr-17-18 08:30AM  MicroCap Review Magazine Spring 2018 Issue Now Available ACCESSWIRE +7.73%
Apr-11-18 12:23PM  Should You Worry About CEL-SCI Corporations (NYSEMKT:CVM) CEO Pay? Simply Wall St.
Apr-09-18 09:45AM  CEL-SCI Corporation to Present at The MicroCap Conference Business Wire
Apr-04-18 08:00AM  CEL-SCI Corporation Issues Letter to Shareholders Business Wire
Apr-03-18 08:30AM  CEL-SCI Announces Adjustment to Warrant Exercise Price Business Wire
Mar-13-18 06:46PM  With A -133.58% Earnings Drop, Is CEL-SCI Corporations (NYSEMKT:CVM) A Concern? Simply Wall St.
Feb-27-18 05:19PM  Who Are CEL-SCI Corporations (NYSEMKT:CVM) Major Shareholders? Simply Wall St.
Feb-23-18 09:00AM  CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016 Business Wire
Feb-12-18 05:35PM  Cel-Sci reports 1Q loss Associated Press
05:20PM  CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results Business Wire
11:00AM  CEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor Conference Business Wire
Feb-05-18 09:30AM  CEL-SCI to Present at 2018 BIO CEO & Investor Conference Business Wire
Jan-30-18 10:00AM  U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology Business Wire
Jan-17-18 07:30AM  Wired News Pluristems PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article ACCESSWIRE
Jan-16-18 08:00AM  CEL-SCI Announces Adjustment to Warrant Exercise Price Business Wire
Jan-08-18 07:50AM  CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis Business Wire
Jan-03-18 07:30AM  CEL-SCI Issues Letter to Shareholders Business Wire
Dec-29-17 04:15PM  CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments Business Wire
08:45AM  What Is The Future Prospect For Healthcare And CEL-SCI Corporation (NYSEMKT:CVM)? Simply Wall St.
Dec-20-17 07:04PM  What Did CEL-SCI Corporations (NYSEMKT:CVM) CEO Take Home Last Year? Simply Wall St. -7.13%
Dec-18-17 07:30AM  CEL-SCI Announces Robert Watson Joins Its Board of Directors Business Wire +6.92%
Dec-11-17 01:30PM  CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study Business Wire +5.06%
Dec-07-17 07:30AM  CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study Business Wire
Nov-29-17 07:17PM  CEL-SCI Corporations (CVM) EPS Grew 65.7% In A Year. Was It Better Than Long-Term Trend? Simply Wall St.
Nov-28-17 09:26AM  CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016 Business Wire
Nov-14-17 09:30AM  Flaherty Financial Newsletter Spotlights "CEL-SCI Corporation's Global Phase 3 Cancer Immunotherapy Treatment Nearing the Finish Line" in Flaherty Financial Newsletter #60 ACCESSWIRE
Nov-13-17 07:30AM  CEL-SCI Announces Update on Arbitration against Former Clinical Research Organization Business Wire
Nov-07-17 10:05AM  ETFs with exposure to CEL-SCI Corp. : November 7, 2017 Capital Cube
Oct-25-17 09:09PM  Who Owns Most Of CEL-SCI Corporation (CVM)? Simply Wall St.
Oct-11-17 11:22AM  ETFs with exposure to CEL-SCI Corp. : October 11, 2017 Capital Cube
Oct-10-17 08:30AM  CEL-SCI Granted European Patent for Multikines Mechanism of Action in Making Tumors Visible to the Immune System Business Wire
Oct-05-17 09:45AM  CEL-SCI Announces Update on Ongoing Arbitration against Former Clinical Research Organization Business Wire
Sep-22-17 10:18AM  ETFs with exposure to CEL-SCI Corp. : September 22, 2017 Capital Cube
Sep-19-17 09:00AM  CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine Business Wire
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CIPRIANO JOHNSenior Vice PresidentSep 17Sale8.698,00069,55983,108Sep 18 05:02 PM
CIPRIANO JOHNSenior Vice PresidentAug 28Sale7.038,00056,20891,108Aug 29 05:14 PM
YOUNG PETER RDirectorMay 21Buy5.002,00010,00021,091May 21 09:18 PM
YOUNG PETER RDirectorApr 05Buy5.202,00010,40019,091Apr 09 04:51 PM
YOUNG PETER RDirectorFeb 14Buy2.821,0002,82017,091Feb 19 10:56 AM
ZIMMERMAN DANIEL HSr. Vice PresidentDec 31Sale2.932,4747,249104,589Jan 02 04:53 PM